Skip to main content
Fig. 5 | Journal of Translational Medicine

Fig. 5

From: A novel immune checkpoints-based signature to predict prognosis and response to immunotherapy in lung adenocarcinoma

Fig. 5

The immune landscape of the novel immune checkpoint-based signature in patients with LUAD. A Estimated immune cell expression proportion in high- and low-risk groups. B and C Detailed information on the different immune cell expression profiles across risk groups. D, F, G, and H The correlation between risk score and several critical immune checkpoints. *, **, and *** represent P < 0.05, P < 0.01, and P < 0.001, respectively

Back to article page